The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice

Cell Metabolism

Volumn 25, Issue 4, 2017, Pages 927-934.e3

  Chambers, Adam P ^a   Sorrell, Joyce E ^b   Haller, April ^b   Roelofs, Karen ^c   Hutch, Chelsea R ^c   Kim, Ki Suk ^c   Gutierrez Aguilar, Ruth ^d   Li, Bailing ^b   Drucker, Daniel J ^e   D'Alessio, David A ^f   Seeley, Randy J ^c   Sandoval, Darleen A ^c  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^e MOUNT SINAI HOSPITAL   (Canada)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GLP 1; glucose homeostasis; incretin

Indexed keywords

EXENDIN[9-39]; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; PREPROGLUCAGON; UNCLASSIFIED DRUG; PROGLUCAGON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; GLUCOSE INTAKE; GLUCOSE INTOLERANCE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE; LOSS OF FUNCTION MUTATION; LOXP SITE; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; TARGET TISSUE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS; PHENOTYPE; REPRODUCIBILITY;

ADMINISTRATION, ORAL; ANIMALS; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GENE TARGETING; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INJECTIONS, INTRAPERITONEAL; MALE; MICE, INBRED C57BL; ORGAN SPECIFICITY; PANCREAS; PHENOTYPE; PROGLUCAGON; REPRODUCIBILITY OF RESULTS;

EID: 85015285693     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.02.008     Document Type: Article

References (27)

1. Ali, S., Lamont, B.J., Charron, M.J., Drucker, D.J., Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J. Clin. Invest. 121 (2011), 1917–1929.
2. Ayala, J.E., Bracy, D.P., McGuinness, O.P., Wasserman, D.H., Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55 (2006), 390–397.
3. Donath, M.Y., Burcelin, R., GLP-1 effects on islets: hormonal, neuronal, or paracrine?. Diabetes Care 36:Suppl 2 (2013), S145–S148.
4. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
5. Edwards, C.M., Todd, J.F., Mahmoudi, M., Wang, Z., Wang, R.M., Ghatei, M.A., Bloom, S.R., Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48 (1999), 86–93.
6. el Marjou, F., Janssen, K.-P., Chang, B.H.-J., Li, M., Hindie, V., Chan, L., Louvard, D., Chambon, P., Metzger, D., Robine, S., Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39 (2004), 186–193.
7. Gelling, R.W., Du, X.Q., Dichmann, D.S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J.J., Fledelius, C., et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U S A 100 (2003), 1438–1443.
8. Gelling, R.W., Vuguin, P.M., Du, X.Q., Cui, L., Rømer, J., Pederson, R.A., Leiser, M., Sørensen, H., Holst, J.J., Fledelius, C., et al. Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E695–E707.
9. Hansen, L.A., Deacon, C., Orskov, C., Holst, J., Glucagon-like peptide-1 (7-36) amide is transformed to GLP-1 (9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 40 (1999), 5356–5363.
10. Hayashi, Y., Yamamoto, M., Mizoguchi, H., Watanabe, C., Ito, R., Yamamoto, S., Sun, X.Y., Murata, Y., Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet alpha-cells but not of intestinal L-cells. Mol. Endocrinol. 23 (2009), 1990–1999.
11. Hira, T., Mochida, T., Miyashita, K., Hara, H., GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 297 (2009), G663–G671.
12. Kahles, F., Meyer, C., Möllmann, J., Diebold, S., Findeisen, H.M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., Lehrke, M., GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63 (2014), 3221–3229.
13. Kilimnik, G., Kim, A., Steiner, D.F., Friedman, T.C., Hara, M., Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of ß-cell regeneration. Islets 2 (2010), 149–155.
14. Lachey, J.L., D'Alessio, D.A., Rinaman, L., Elmquist, J.K., Drucker, D.J., Seeley, R.J., The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 146 (2005), 458–462.
15. Marchetti, P., Lupi, R., Bugliani, M., Kirkpatrick, C.L., Sebastiani, G., Grieco, F.A., Del Guerra, S., D'Aleo, V., Piro, S., Marselli, L., et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55 (2012), 3262–3272.
16. Masur, K., Tibaduiza, E.C., Chen, C., Ligon, B., Beinborn, M., Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol. Endocrinol. 19 (2005), 1373–1382.
17. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., Gallwitz, B., Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 (2004), 654–662.
18. Salehi, M., Aulinger, B., Prigeon, R.L., D'Alessio, D.A., Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 59 (2010), 1330–1337.
19. Salehi, M., Aulinger, B., D'Alessio, D.A., Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes 61 (2012), 2728–2733.
20. Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., Katschinski, M., Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J. Clin. Invest. 101 (1998), 1421–1430.
21. Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H.J., Göke, B., Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55 (2006), 243–251.
22. Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., Drucker, D.J., Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2 (1996), 1254–1258.
23. Serre, V., Dolci, W., Schaerer, E., Scrocchi, L., Drucker, D., Efrat, S., Thorens, B., Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology 139 (1998), 4448–4454.
24. Shigeto, M., Ramracheya, R., Tarasov, A.I., Cha, C.Y., Chibalina, M.V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. J. Clin. Invest. 125 (2015), 4714–4728.
25. Smith, E.P., An, Z., Wagner, C., Lewis, A.G., Cohen, E.B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19 (2014), 1050–1057.
26. Whalley, N.M., Pritchard, L.E., Smith, D.M., White, A., Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?. J. Endocrinol. 211 (2011), 99–106.
27. Wilson-Pérez, H.E., Chambers, A.P., Ryan, K.K., Li, B., Sandoval, D.A., Stoffers, D., Drucker, D.J., Pérez-Tilve, D., Seeley, R.J., Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes 62 (2013), 2380–2385.